Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 2.61%

The earnings report shows that Alnylam Pharmaceuticals did not meet EPS expectations, which typically raises concerns among investors. However, the stock rose by 2.61%, indicating that investors may be optimistic about the company's future prospects and pipeline developments. The lack of revenue data and guidance leaves some uncertainty, but management's positive outlook may have reassured investors.